MedTrace Logo

The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings

NCT00830570 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1635

Last updated 2010-11-16

No results posted yet for this study

Summary

The purpose of this quasi-experiment study, which could also be classified as a prospective observational intervention study, is to assess the impact of cytochrome P450 2C9 (CYP 2C9) and vitamin K epoxide reductase complex, subunit 1 (VKORC1) testing within a primary patient care setting.

Conditions

  • Embolism and Thrombosis
  • Embolism
  • Vascular Diseases
  • Warfarin
  • Venous Thromboembolism
  • Thrombosis
  • Thromboembolism

Interventions

OTHER

CYP 2C9 and VKORC1 Testing for Warfarin

Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.

Sponsors & Collaborators

  • Mayo Clinic

    collaborator OTHER

  • Washington University School of Medicine

    collaborator OTHER

  • Medco Health Solutions, Inc.

    lead INDUSTRY

Principal Investigators

  • Robert Epstein, MD, MS · Medco Health Solutions, Inc.

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00830570 on ClinicalTrials.gov